Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 2/20 | 0.48 |
| ▸ | F2R | P25116 | 2/20 | 0.45 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | GRB2 | P62993 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29582550 | 0.95 | BDKRB2 (0.48) | BDKRB2F2RBDKRB1NTSR1QRFPR | |
| SCHEMBL29457591 | 0.94 | F2R (0.48) | BDKRB2F2RNTSR1ITGB3ITGA2B | |
| SCHEMBL30321462 | 0.91 | F2R (0.48) | BDKRB2F2RNTSR1F2GRB2 | |
| SCHEMBL29367074 | 0.90 | BDKRB2 (0.50) | BDKRB2NTSR1F2GRB2 | |
| SCHEMBL29377971 | 0.90 | F2 (0.55) | BDKRB2NTSR1F2GRB2 | |
| SCHEMBL28923852 | 0.90 | BDKRB2 (0.50) | BDKRB2NTSR1F2GRB2 | |
| SCHEMBL29462901 | 0.89 | KEAP1 (0.46) | NTSR1ITGB3ITGA2BF2GRB2 | |
| SCHEMBL29364214 | 0.89 | KEAP1 (0.46) | NTSR1ITGB3ITGA2BF2GRB2 | |
| SCHEMBL2790798 | 0.88 | CXCR4 (0.45) | — | |
| SCHEMBL12680175 | 0.88 | CXCR4 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090414-A1 | SIRNA DELIVERY FOR POLYCYSTIC KIDNEY DISEASE THERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260102435-A1 | ENGINEERED CELLS AND IMPLANTABLE ELEMENTS FOR TREATMENT OF DISEASE | SIGILON THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | claimed |
| US-20260083817-A1 | PEPTIDE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF SKIN AND MUCOUS MEMBRANE WOUNDS AND IN COSMETIC APPLICATIONS | 3-D MATRIX, LTD. (US) | 2026-03-26 | — | — | US | claimed |
| US-20260014283-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY AND METHODS OF USING THE SAME | PENN STATE RES FOUND (US) | 2026-01-15 | — | — | US | claimed |
| EP-4628528-A1 | ALGINATE HYDROGEL PARTICLES FOR CELL CULTURE APPLICATIONS | Nutrition & Biosciences USA 1, LLC (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3856154-B1 | IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS | SIGILON THERAPEUTICS INC (US) | 2025-08-27 | — | — | EP | claimed |
| EP-4602155-A1 | ENGINEERED CELLS AND IMPLANTABLE ELEMENTS FOR TREATMENT OF DISEASE | Sigilon Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | claimed |
| EP-4602154-A1 | ENGINEERED CELLS AND IMPLANTABLE ELEMENTS FOR TREATMENT OF DISEASE | Sigilon Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | claimed |
| US-20250242078-A1 | NOVEL POLYMER | SWINBURNE UNIVERSITY OF TECHNOLOGY (AU) | 2025-07-31 | — | — | US | claimed |
| CN-120035657-A | Engineered cells and implantable elements for treating diseases | 西吉隆医疗股份有限公司 | 2025-05-23 | — | — | CN | claimed |
| WO-2022164928-A2 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES | SIGILON THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | claimed |
| WO-2022164933-A2 | BIOCOMPATIBLE DEVICES FOR CELL-BASED THERAPIES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | claimed |
| WO-2022164931-A2 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE | SIGILON THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | claimed |
| US-11364321-B2 | Nano scale decoration of scaffold-free microtissue using functionalised gold nanostructures | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-06-21 | — | — | US | claimed |
| WO-2022026606-A9 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | claimed |
| CN-114222590-A | Compositions, devices and methods for factor VII therapy | 西吉隆医疗股份有限公司 | 2022-03-22 | — | — | CN | claimed |
| EP-3946463-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | Sigilon Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| EP-3946433-A1 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING FABRY DISEASE | Sigilon Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| WO-2022026606-A2 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2022027020-A2 | ARTIFICIAL PLACENTA VACCINE FOR ORGAN TRANSPLANTATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102435-A1 | ENGINEERED CELLS AND IMPLANTABLE ELEMENTS FOR TREATMENT OF DISEASE | CD74, IL2RA, HLA-C | BDKRB2 2868/4885F2R 832/4885BDKRB1 2532/4885 |
| US-20260083817-A1 | PEPTIDE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF SKIN AND MUCOUS MEMBRANE WOUNDS AND IN COSMETIC APPLICATIONS | CUTA, RAD1, COL14A1 | BDKRB2 637/4885F2R 1245/4885BDKRB1 512/4885 |
| US-20260014283-A1 | ULTRASOUND-SENSITIVE PEPTIDE PARTICLES FOR SPATIALLY RESOLVED MOLECULE DELIVERY AND METHODS OF USING THE SAME | HDGFL3, HDGF, HM13 | BDKRB2 2113/4885F2R 2018/4885BDKRB1 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.